Tag: 689 nm

Peptide-Drug Conjugate for Therapeutic Reprogramming of Tumor-Associated Macrophages in Breast Cancer

Scientific papers / 689 nm, breast cancer, immunology, immunotherapy, in vitro, in vivo, ML6600, photosensitizer, tumor, verteporfin

Published in: Advanced Science Authors: Anni Lepland, Elisa Peranzoni, Uku Haljasorg, Eliana K. Asciutto, Maria Crespí-Amer, Lorenzo Modesti, Kalle Kilk, Manuel Lombardia, Gerardo Acosta, Miriam Royo, Pärt Peterson, Ilaria Marigo, Tambet Teesalu, Pablo Scodeller

Peptide-Drug Conjugate for Therapeutic Reprogramming of Tumor-Associated Macrophages in Breast Cancer Read More »

Novel ophthalmic laser system paired with focal electroretinography for subthreshold laser therapy of DME

Scientific papers / 689 nm, age-related macular degeneration, AMD, BIOS, clinical trials, DME, fERG, focal electroretinography, fundus imaging, ML6710i, Modulight authors, Modulight Cloud, ophthalmic treatments, retinal diseases, SPIE BIOS 2023, thermal dosimetry

Presented in: SPIE BIOS 2023 Authors: Jukka-Pekka Alanko, Eero Koivumäki, Laura Vesala, Johannes Kivelä, Zoe Ylöniemi, Petteri Uusimaa, Ossi Kaikkonen, Teemu Turunen, Jaakko Nieminen, Jani Tirronen

Novel ophthalmic laser system paired with focal electroretinography for subthreshold laser therapy of DME Read More »

Optimized light delivery in pancreatic cancer

Application Note / 689 nm, in vivo, interstitial, ML7710, pancreas, pancreatic cancer, phototherapy, tumor, University of California at Irvine

Motivation for the study Efficient light delivery to the whole tumor is one of the main aspects of phototherapy. The efficacy of phototherapy has been demonstrated for several cancers via superficial illumination. Interstitial illumination could enhance light delivery deeper inside the tumor and potentially result in more effective tumor eradication. Hence, the aim of this

Optimized light delivery in pancreatic cancer Read More »

Light penetration depth in brain with different photosensitizers

Application Note / 5-ALA, 635 nm, 689 nm, BPD, brain cancer, glioblastoma, ML6600, PDT, Photoimmunotherapy, PIT, PPIX, University of Maryland, verteporfin

Motivation for the study Glioblastoma is the most aggressive and lethal brain cancer with an average prognosis of 15 months. Fluorescence-guided surgery (FGS) for glioblastoma was FDA-approved in 2017, while photodynamic therapy (PDT) remains an active area of clinical investigation with very promising results so far. The aim of PDT is to eradicate the

Light penetration depth in brain with different photosensitizers Read More »

Protected: In-vivo distribution and vascular & tumor responses

subscriber / 689 nm, Erasmus MC, ML7710, University Medical Center Rotterdam, University of Groningen

There is no excerpt because this is a protected post.

Protected: In-vivo distribution and vascular & tumor responses Read More »

Protected: New approach for targeted PDT of glioblastoma

subscriber / 689 nm, Erasmus MC, Leiden University, ML6500, ML7710, Utrecht University

There is no excerpt because this is a protected post.

Protected: New approach for targeted PDT of glioblastoma Read More »

Development of heat shock protein 90-targeted PDT for inflammatory breast cancer

Application Note / 665 nm, 689 nm, 750 nm, breast cancer, Duke University, HS201, HSP90, in vitro, in vivo, ML7710, ML8500, verteporfin

Motivation of the study In photodynamic therapy (PDT), systemically administered photosensitizer is activated within the tumor using focused near-infrared light, typically a laser with a wavelength matching the absorption peak of the photosensitizer. Several photosensitizers have been clinically approved for the treatment of different cancers; however, their accumulation is non-tumor exclusive which exposes healthy tissues

Development of heat shock protein 90-targeted PDT for inflammatory breast cancer Read More »